Selected article for: "active metabolite and acute respiratory syndrome coronavirus"
Author: Yang, Katherine
Title: What do we know about remdesivir drug interactions?
  • Cord-id: 5ijdl5sl
  • Document date: 2020_5_13
    • ID: 5ijdl5sl
    Snippet: The global pandemic of severe acute respiratory syndrome coronavirus 2 (SARS‐Co‐V‐2) has resulted in a critical need to rapidly develop new pharmacologic interventions and disseminate information. This has led to confusing and conflicting information on drug efficacy. Remdesivir has emerged as a promising treatment for SARS‐Co‐V‐2 infection yet published clinical pharmacology and drug interaction studies are limited. Additional studies of the disposition of remdesivir, its active met
    Document: The global pandemic of severe acute respiratory syndrome coronavirus 2 (SARS‐Co‐V‐2) has resulted in a critical need to rapidly develop new pharmacologic interventions and disseminate information. This has led to confusing and conflicting information on drug efficacy. Remdesivir has emerged as a promising treatment for SARS‐Co‐V‐2 infection yet published clinical pharmacology and drug interaction studies are limited. Additional studies of the disposition of remdesivir, its active metabolite (GS‐441524), and its triphosphate metabolite (GS‐443902) are needed.

    Search related documents:
    Co phrase search for related documents
    • abnormal liver function and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • abnormal liver function test and liver function: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • abnormal liver function test and lopinavir ritonavir: 1
    • active form and liver function: 1
    • active form and low potential: 1, 2
    • active metabolite and liver function: 1, 2, 3
    • active metabolite and lopinavir ritonavir: 1
    • active metabolite and low potential: 1, 2, 3, 4
    • liver function and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23